Chimerix (NASDAQ:CMRX) Sets New 12-Month High – Should You Buy?

Chimerix, Inc. (NASDAQ:CMRX) reached a new 52-week high on Tuesday . The stock traded as high as $8.55 and last traded at $8.55, with a volume of 805519 shares trading hands. The stock had previously closed at $8.54.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on CMRX. Jefferies Financial Group reiterated a “hold” rating and issued a $8.50 price objective (down previously from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th. HC Wainwright reaffirmed a “neutral” rating and set a $8.55 price objective (down from $11.00) on shares of Chimerix in a report on Wednesday, March 5th. StockNews.com initiated coverage on shares of Chimerix in a research report on Wednesday. They set a “hold” rating for the company. Finally, Wedbush reiterated a “neutral” rating and issued a $8.55 price target (up previously from $7.00) on shares of Chimerix in a research note on Wednesday, March 5th.

Chimerix Stock Performance

The company’s fifty day moving average price is $7.22 and its 200-day moving average price is $3.87. The stock has a market cap of $801.09 million, a P/E ratio of -9.09 and a beta of -0.17.

Chimerix (NASDAQ:CMRX) last released its earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.01. The business had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.31 million. Analysts anticipate that Chimerix, Inc. will post -0.99 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Michael T. Andriole sold 7,370 shares of Chimerix stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the sale, the chief executive officer now directly owns 609,603 shares in the company, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders sold 20,760 shares of company stock worth $91,175 in the last three months. 13.10% of the stock is owned by insiders.

Institutional Trading of Chimerix

Several large investors have recently made changes to their positions in the business. Bender Robert & Associates acquired a new stake in shares of Chimerix during the 4th quarter worth approximately $37,000. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Chimerix in the 4th quarter valued at approximately $59,000. Jane Street Group LLC purchased a new position in shares of Chimerix during the fourth quarter worth $62,000. Diadema Partners LP acquired a new stake in shares of Chimerix in the fourth quarter valued at $101,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Chimerix in the 4th quarter valued at $130,000. 45.42% of the stock is owned by hedge funds and other institutional investors.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.